Article info
PDFCorrespondence response
Response to: Comment on l’Ami et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder et al
- Correspondence to Merel J l’Ami, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam 1056 AB, The Netherlands ; m.lami{at}reade.nl
Citation
Response to: Comment on l’Ami et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder et al
Publication history
- Received November 3, 2017
- Accepted November 4, 2017
- First published November 13, 2017.
Online issue publication
June 30, 2020
Article Versions
- Previous version (30 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.